Heart Disease Trial, Recruiting NCT04983823 Sponsor: Baker Heart and Diabetes Institute Condition: Heart Disease
Back to Heart Disease

Heart Disease Trial, Recruiting

NCT04983823
Recruiting Not Applicable 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have previously had a COVID-19 infection
  • People who live close enough to the trial site to attend follow-up appointments

Who may not be able to join:

  • People who have a moderate or severe problem with one or more heart valves (either narrowing or leaking)
  • People who have previously been diagnosed with heart failure, specifically those with more significant limitations on physical activity (confirm with trial site)
  • People whose heart cannot be clearly seen on an ultrasound scan, as identified during an initial scan
  • People for whom certain common heart medications — beta blockers or ACE inhibitors — are not medically suitable
  • People whose life expectancy is less than 12 months due to cancer or another serious illness, or people with any other medical condition (including pregnancy) that the trial's lead researchers consider makes participation unsuitable
  • People who are already taking both an ACE inhibitor or ARB (a type of blood pressure medication) and a beta blocker at the same time, or people who cannot tolerate or are allergic to both types of medication
  • People with a physical condition affecting mobility that would make it difficult to perform exercise as part of the trial
  • People who are unable to provide written consent to take part in the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Thomas H Marwick, MD,PhD,MPH, Baker Heart and Diabetes Institute

Phone: +61385321964

Australian sites

Baker Heart and Diabetes Institute, Melbourne, Victoria
+61385321550

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Baker Heart and Diabetes Institute
Registry
ClinicalTrials.gov
Start date
18 November 2021
Est. completion
30 July 2025

Where this trial is recruiting

🇦🇺 Australia

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Change in exercise capacity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov